News & Updates

Aspirin monotherapy sufficient for venous thromboembolism prevention after arthroplasty

In patients who have undergone total hip or total knee arthroplasty, postoperative treatment with aspirin alone is as good as a strategy of using rivaroxaban followed by aspirin in terms of preventing symptomatic venous thromboembolism, with no significant difference in bleeding events, according to the EPCAT III trial.

Encapsulated rapamycin a promising chemopreventive agent in familial adenomatous polyposis

In patients with familial adenomatous polyposis (FAP), treatment with encapsulated rapamycin is safe and appears to lower polyp burden, according to a phase II study.

Sotatercept increases exercise tolerance in PAH

Patients with pulmonary arterial hypertension treated with sotatercept demonstrate improved exercise tolerance, driven in part by increased haemoglobin, according to a study.

Dexamethasone eye drops show promise in type 1 retinopathy of prematurity

Treatment with dexamethasone eye drops is safe and may reduce the need for invasive treatment in preemies with type 1 retinopathy of prematurity (ROP), according to the DROPROP study.

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

Treatment with STRIDE*, with or without lenvatinib, plus TACE** significantly improves progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) in patients with embolization-eligible hepatocellular carcinoma (eeHCC) compared with TACE alone, according to the phase III EMERALD-3 trial presented at ESMO GI 2026.

Add-on high-dose vitamin D3 of little benefit in mCRC

Adding high-dose vitamin D3 to standard chemotherapy does not appear to improve outcomes in patients with previously untreated metastatic colorectal cancer (mCRC), as shown in a phase III trial.

IVF treatment linked to mental health vulnerability

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

Treatment with the oral orexin receptor 2 (OX2R) agonist oveporexton improves symptom control, daily function, and cognitive outcomes in patients with narcolepsy type 1, according to pooled data from two phase III studies, The First Light and The Radiant Light.